Lambert-Eaton Myasthenic Syndrome clinical trials
The registry lists 22 studies for Lambert-Eaton Myasthenic Syndrome across more than 10 countries. 5 are recruiting or about to start. 14 of them are mainly about Lambert-Eaton Myasthenic Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Lambert-Eaton Myasthenic Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Catalyst Pharmaceuticals, Inc. (3) · LMU Klinikum (2) · FDA Office of Orphan Products Development (1) · Louis H. Weimer, MD (1) · David Lacomis, MD (1) · Oregon Health and Science University (1) · Heinrich-Heine University, Duesseldorf (1) · Jacobus Pharmaceutical (1)
What is being tested here
Drugs under test in Lambert-Eaton Myasthenic Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Amifampridine | 0 | 2 | 4 |
| Antilymphocyte Serum | 0 | 0 | 1 |
| Carmustine | 0 | 0 | 1 |
| Cytarabine | 0 | 0 | 1 |
| Etoposide | 0 | 0 | 1 |
| Melphalan | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 3 Lambert-Eaton Myasthenic Syndrome studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 22 studies, recruiting or not: 18% stop at 75 or younger and 14% at 65; 23% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular DisordersEnrolling by invitationNCT066056121 country
- Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyRecruitingNCT07136844Not applicable1 country
- The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.Enrolling by invitationNCT07072676Not applicable1 country
- Patient Observation With Environmental and Wearable Sensors in Myasthenia GravisRecruitingNCT064418251 country
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseActive, not recruitingNCT07478172Not applicable1 country
- A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)WithdrawnNCT070756271 country
- Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesActive, not recruitingNCT00716066Phase 21 country
- Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic SyndromeApproved for marketingNCT021897201 country
- Exercise in Autoimmune Myasthenia Gravis and Myasthenic SyndromesCompletedNCT054087021 country
- 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)Approved for marketingNCT008729501 country
- Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton SyndromeApproved for marketingNCT018253951 country
- 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)No longer availableNCT020129331 country
- Treatment of Lambert-Eaton Syndrome With 3,4 DAPNo longer availableNCT007049251 country
- Treatment of Lambert-Eaton Syndrome With 3,4 DiaminopyridineNo longer availableNCT00994916
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)CompletedNCT02970162Phase 31 country
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedNCT01377922Phase 38 countries
- Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeCompletedNCT01511978Phase 21 country
- Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic SyndromeNo longer availableNCT013733331 country
- Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic SyndromeCompletedNCT00004832Not applicable
- National Registry for Egyptian Pediatric Neuromuscular DiseasesStatus unknownNCT021246161 country
- Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAPNo longer availableNCT013785461 country